Elena Raschi

List of Publications by Year
in descending order

63	4,136	126708	189595
papers	citations	33 h-index	50 g-index

65	65	65	2880
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nature Reviews Rheumatology, 2011, 7, 330-339.	3.5	482
2	Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered Î²2-glycoprotein I. Arthritis and Rheumatism, 2000, 43, 140-150.	6.7	290
3	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood, 2003, 101, 3495-3500.	0.6	290
4	Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878.	6.7	250
5	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. Seminars in Thrombosis and Hemostasis, 2008, 34, 236-250.	1.5	205
6	Infectious origin of the antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2006, 65, 2-6.	0.5	203
7	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Annals of the Rheumatic Diseases, 2007, 66, 1327-1333.	0.5	184
8	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. American Journal of Kidney Diseases, 2001, 37, 490-498.	2.1	168
9	Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome. Journal of Autoimmunity, 2000, 15, 237-240.	3.0	139
10	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis and Rheumatism, 2002, 46, 1602-1613.	6.7	137
11	Endothelium and the brain in CNS lupus. Lupus, 2003, 12, 919-928.	0.8	102
12	Pathogenic role of anti-Â2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of Â2-glycoprotein I binding to trophoblast cells and functional effects of anti-Â2-glycoprotein I antibodies in vitro. Annals of the Rheumatic Diseases, 2004, 64, 462-467.	0.5	97
13	Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. Journal of Immunology, 1998, 160, 5572-8.	0.4	94
14	Endothelial cell activation by antiphospholipid antibodies. Clinical Immunology, 2004, 112, 169-174.	1.4	91
15	Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus, 1999, 8, 423-429.	0.8	85
16	Interleukinâ€17A+ Cell Counts Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated With the Extent of Skin Involvement. Arthritis and Rheumatism, 2013, 65, 1347-1356.	6.7	85
17	Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Research and Therapy, 2013, 15, R151.	1.6	74
18	Inflammatory response and the endothelium. Thrombosis Research, 2004, 114, 329-334.	0.8	68

#	Article	IF	Citations
19	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus, 2008, 17, 938-943.	0.8	63
20	Î²2-Glycoprotein I as a â€˜Cofactorâ€™ for anti-phospholipid reactivity with endothelial cells. Lupus, 1998, 7, 44-47.	0.8	54
21	Î²2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. Journal of Autoimmunity, 2014, 55, 42-50.	3.0	52
22	Decreased expression of heparinâ€binding epidermal growth factorâ€“like growth factor as a newly identified pathogenic mechanism of antiphospholipidâ€mediated defective placentation. Arthritis and Rheumatism, 2010, 62, 1504-1512.	6.7	51
23	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmunity Reviews, 2004, 3, 510-515.	2.5	50
24	Humoral autoimmunity against endothelium: theory or reality?. Trends in Immunology, 2005, 26, 275-281.	2.9	50
25	Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Antiâ€Beta 2 Glycoprotein I Antibodies. American Journal of Reproductive Immunology, 1997, 38, 212-217.	1.2	49
26	ANTIPHOSPHOLIPID ANTIBODIES AND THE ENDOTHELIUM. Rheumatic Disease Clinics of North America, 2001, 27, 587-602.	0.8	49
27	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. International Immunology, 2001, 13, 349-357.	1.8	45
28	Endothelium as a target for antiphospholipid antibodies. Immunobiology, 2003, 207, 29-36.	0.8	45
29	Obstetric and vascular APS: Same autoantibodies but different diseases?. Lupus, 2012, 21, 708-710.	0.8	41
30	Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis and Rheumatism, 2002, 46, 1595-1601.	6.7	40
31	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica, 2019, 104, 819-826.	1.7	40
32	Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss. Clinical Reviews in Allergy and Immunology, 2008, 34, 332-337.	2.9	38
33	Update on the pathogenesis and treatment of the antiphospholipid syndrome. Current Opinion in Rheumatology, 2015, 27, 476-482.	2.0	35
34	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Research and Therapy, 2018, 20, 187.	1.6	33
35	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 265.	1.6	33
36	The challenges of lupus anticoagulants. Expert Review of Hematology, 2016, 9, 389-400.	1.0	31

#	Article	IF	Citations
37	Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. Clinical and Experimental Immunology, 1997, 110, 479-484.	1.1	29
38	Anti-Beta-2 Glycoprotein I Antibodies Affect Bcl-2 and Bax Trophoblast Expression without Evidence of Apoptosis. Annals of the New York Academy of Sciences, 2006, 1069, 364-376.	1.8	28
39	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. Journal of Autoimmunity, 2009, 32, 60-63.	3.0	28
40	Anti-endothelial cell antibodies in patients with coronary atherosclerosis. Immunology Letters, 2000, 73, 23-27.	1.1	26
41	Transforming growth factor Î²1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. Arthritis and Rheumatism, 2006, 54, 356-359.	6.7	25
42	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. Transplantation, 2008, 86, 1445-1451.	0.5	24
43	Plasma levels of soluble endothelial cell protein C receptor in patients with Wegenerâ€™s granulomatosis. Clinical and Experimental Immunology, 2002, 128, 187-194.	1.1	23
44	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 67-73.	2.9	23
45	Toll-like receptor 4 and Î²₂ glycoprotein I interaction on endothelial cells. Lupus, 2014, 23, 1302-1304.	0.8	23
46	Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. Autoimmunity Reviews, 2002, 1, 55-60.	2.5	19
47	Endothelium activation in the anti-phospholipid syndrome. Biomedicine and Pharmacotherapy, 2003, 57, 282-286.	2.5	18
48	Antiendothelial Cell Antibodies (AECA): From a Laboratory Curiosity to Another Useful Autoantibody. , 1999, , 285-294.		8
49	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. Open Rheumatology Journal, 2018, 12, 248-260.	0.1	5
50	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES. , 2007, , 725-731.		4
51	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2009, 10, 55-67.	0.1	4
52	Functional Heterogeneity of Pathogenic Anti-Endothelial Cell Antibodies. , 2001, , 211-220.		2
53	Mechanisms of Action of the Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2017, 12, 31-46.	0.1	1
54	Antiphospholipid/Endothelial Cell Interaction in the Pathogenesis of the Antiphospholipid Syndrome. , 2002, , 79-89.		1

#	Article	IF	Citations
55	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
56	What are the Target Cells and Receptors that are Recognized by Antiphospholipid Antibodies?. , 2012, , 103-113.		1
57	The Story of the Murine Antiendothelial Monoclonal Antibody BGM : From Patients' Bedside to Laboratory Bench and From Animal Models to Patients. Clinical Reviews in Allergy and Immunology, 2000, 18, 3-10.	2.9	0
58	OP0060â€...Beta2GPI and TLR4 interaction on endothelial cells: A bridge between innate and adaptive immunity in APS. Annals of the Rheumatic Diseases, 2013, 71, 73.2-73.	0.5	0
59	A3.5â€...Toll like receptors: a crossroad in scleroderma etiopathogenesis. Annals of the Rheumatic Diseases, 2014, 73, A43.2-A44.	0.5	0
60	Antiendothelial Cell Antibodies. , 2014, , 723-729.		0
61	OP0285â€...The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease. Annals of the Rheumatic Diseases, 2015, 74, 180.2-180.	0.5	0
62	AB0201â€...THE PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC AUTOANTIBODIES IN ENDOTHELIAL CELLS. , 2019, , .		0
63	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 67-73.	2.9	0